CompletedPhase 3ACTRN12607000301460

The effects of nebulised N-acetylcysteine on sputum quality and diagnostic yield: a randomised, controlled clinical trial

A randomised clinical trial to compare the efficacy of nebulized N-acetylcysteine and normal saline in improving sputum quality and diagnostic yield in patients with chest infections.

Sponsor

Austin Health

Enrollment

190 participants

Start Date

Aug 1, 2007

Study Type

Interventional

Conditions

Sputum quality, chest infections

Summary

We believe that the use of N-acetylcysteine (a known mucolytic) will be useful in improving the diagnostic yield of sputum culture. If this hypothesis is proven, this agent can be recommend for this purpose.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This trial tests whether inhaling nebulised N-acetylcysteine (NAC) can improve the quality of sputum samples collected in the emergency department from patients with suspected lower respiratory tract infections. It is for adults aged 18 and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Single dose of 5 ml (200mg/ml) of nebulized N-acetylcysteine (intervention).

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000301460